GENEREX
BIOTECHNOLOGY CORPORATION
|
(Exact
Name of Registrant as Specified in Its
Charter)
|
Delaware
|
000-25169
|
98-0178636
|
(State
or Other
|
(Commission
|
(IRS
Employer
|
Jurisdiction
of
|
File
Number)
|
Identification
|
Incorporation)
|
|
Number)
|
|
|
|
|
|
|
33
Harbour Square, Suite 202, Toronto, Ontario Canada
|
M5J
2G2
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
|
|
|
|
|
|
|
Registrant’s
telephone number, including area code: (416)
364-2551
|
||
|
|
|
|
|
|
N/A
|
||
(Former
name or former address, if changed since last
report.)
|
Item 9.01
|
Financial
Statements and Exhibits.
|
|
(d)
|
Exhibits
|
99.1
|
Press
Release of Generex Biotechnology Corporation., dated July 25, 2008,
reporting Generex’s receipt of Nasdaq notice dated July 23, 2008.
Filed herewith.
|
GENEREX
BIOTECHNOLOGY CORPORATION
|
||
|
|
|
Date: July
25, 2008
|
By: | /s/ Rose C. Perri |
|
||
Chief
Operating Officer and
Chief
Financial Officer
(principal
financial officer)
|